3-Thiotrisescaline
Pharmaceutical compound
From Wikipedia, the free encyclopedia
3-Thiotrisescaline (3-T-TRIS), also known as 3-thiotrescaline or as 3-ethylthio-4,5-diethoxyphenethylamine, is a chemical compound of the phenethylamine and scaline families related to mescaline.[1][2][3][4] It is the analogue of trisescaline (TRIS; trescaline) in which the ethoxy group at the 3 position has been replaced with an ethylthio group.[1][2][3][4] The drug is one of two possible thiotrisescaline (T-TRIS; thiotrescaline) positional isomers, the other being 4-thiotrisescaline (4-T-TRIS; 4-thiotrescaline).[1][2][3][4]
- None
 | |
| Clinical data | |
|---|---|
| Other names | 3-T-TRIS; 3-Thiotrescaline; 3-Ethylthio-4,5-diethoxyphenethylamine; 3,4-Diethoxy-5-ethylthiophenethylamine |
| Routes of administration | Oral[1] |
| ATC code |
|
| Pharmacokinetic data | |
| Duration of action | Unknown[1] |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C14H23NO2S |
| Molar mass | 269.40 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
In his book PiHKAL (Phenethylamines I Have Known and Loved) and other publications, Alexander Shulgin lists 3-T-TRIS's dose as greater than 160 mg orally and its duration as unknown.[1][2][3] 3-T-TRIS produced no effects at tested doses of up to 160 mg orally, with the exception of possible neurological irritability 9 or 10 hours after administration.[1] Shulgin concluded that the compound is inactive.[1]
The chemical synthesis of 3-T-TRIS has been described.[1][4]
3-T-TRIS was first described in the scientific literature by Shulgin and Peyton Jacob III in 1984.[4] Subsequently, it was described in greater detail by Shulgin in PiHKAL in 1991.[1]